[
  {
    "ts": null,
    "headline": "Zepbound Boost Gets a Lift From Arrowhead’s Drug. The Question Is Whether Patients Will Pay.",
    "summary": "Arrowhead’s experimental therapy helped patients on Lilly’s Zepbound lose more weight and visceral fat—but cost and convenience could limit demand.",
    "url": "https://finnhub.io/api/news?id=fd626fd724e3e75ab7b73718e147db826387e5a50b5d7dd7413210c1381b7e71",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767716760,
      "headline": "Zepbound Boost Gets a Lift From Arrowhead’s Drug. The Question Is Whether Patients Will Pay.",
      "id": 138001894,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Arrowhead’s experimental therapy helped patients on Lilly’s Zepbound lose more weight and visceral fat—but cost and convenience could limit demand.",
      "url": "https://finnhub.io/api/news?id=fd626fd724e3e75ab7b73718e147db826387e5a50b5d7dd7413210c1381b7e71"
    }
  },
  {
    "ts": null,
    "headline": "Google Stock, Lilly And An Aviation Name Are Fund Managers' Favorites",
    "summary": "IBD SwingTrader name Alphabet and IBD 50 watchlist stock Eli Lilly have made the IBD Screen Of The Day, which is focused on Stocks That Funds Are Buying. Google stock is nearing the buy point of a flat base, while Lilly shares pulled back Monday on competitor Novo Nordisk's breakthrough drug launch.",
    "url": "https://finnhub.io/api/news?id=0885c5a3189c766bdd15e26b1987105aa24d0f42d22cc9f65dd3b8c999023ec7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767716352,
      "headline": "Google Stock, Lilly And An Aviation Name Are Fund Managers' Favorites",
      "id": 138001835,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "IBD SwingTrader name Alphabet and IBD 50 watchlist stock Eli Lilly have made the IBD Screen Of The Day, which is focused on Stocks That Funds Are Buying. Google stock is nearing the buy point of a flat base, while Lilly shares pulled back Monday on competitor Novo Nordisk's breakthrough drug launch.",
      "url": "https://finnhub.io/api/news?id=0885c5a3189c766bdd15e26b1987105aa24d0f42d22cc9f65dd3b8c999023ec7"
    }
  },
  {
    "ts": null,
    "headline": "Can the US Launch of NVO's Wegovy Pill Reignite Momentum in 2026?",
    "summary": "Novo Nordisk shares jump after the U.S. launch of its FDA-approved Wegovy pill, giving the first oral GLP-1 weight-loss drug a chance to revive 2026 momentum.",
    "url": "https://finnhub.io/api/news?id=2b5ce34ec00f7f7fa55085447888425bfd3f553d7c1d2ff5da7ba38dd1f2584d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767710460,
      "headline": "Can the US Launch of NVO's Wegovy Pill Reignite Momentum in 2026?",
      "id": 138001896,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk shares jump after the U.S. launch of its FDA-approved Wegovy pill, giving the first oral GLP-1 weight-loss drug a chance to revive 2026 momentum.",
      "url": "https://finnhub.io/api/news?id=2b5ce34ec00f7f7fa55085447888425bfd3f553d7c1d2ff5da7ba38dd1f2584d"
    }
  },
  {
    "ts": null,
    "headline": "Should You Buy Eli Lilly Before It Reaches $1 Trillion in Market Value?",
    "summary": "Eli Lilly offers investors safety and growth.",
    "url": "https://finnhub.io/api/news?id=5e0f3f91b33dcfb03df526a2dec913e09b3acdc337d79db776f6a7be4a1df25e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767709800,
      "headline": "Should You Buy Eli Lilly Before It Reaches $1 Trillion in Market Value?",
      "id": 138000585,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly offers investors safety and growth.",
      "url": "https://finnhub.io/api/news?id=5e0f3f91b33dcfb03df526a2dec913e09b3acdc337d79db776f6a7be4a1df25e"
    }
  },
  {
    "ts": null,
    "headline": "Nimbus Therapeutics Announces Research Collaboration and License Agreement with Lilly for Novel Oral Obesity Treatment",
    "summary": "BOSTON, January 06, 2026--Nimbus Therapeutics, LLC (\"Nimbus Therapeutics\" or \"Nimbus\"), a drug discovery company developing breakthrough medicines through its AI-enhanced computational drug discovery engine, today announced it has entered into a multi-year research collaboration and exclusive, worldwide license agreement with Eli Lilly and Company (\"Lilly\") to develop a novel oral treatment for obesity and other metabolic diseases.",
    "url": "https://finnhub.io/api/news?id=f77f584378aab4133bc810c2d27c9f69b79fd2725fa985c896f04c17cef00b54",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767704400,
      "headline": "Nimbus Therapeutics Announces Research Collaboration and License Agreement with Lilly for Novel Oral Obesity Treatment",
      "id": 138000126,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "BOSTON, January 06, 2026--Nimbus Therapeutics, LLC (\"Nimbus Therapeutics\" or \"Nimbus\"), a drug discovery company developing breakthrough medicines through its AI-enhanced computational drug discovery engine, today announced it has entered into a multi-year research collaboration and exclusive, worldwide license agreement with Eli Lilly and Company (\"Lilly\") to develop a novel oral treatment for obesity and other metabolic diseases.",
      "url": "https://finnhub.io/api/news?id=f77f584378aab4133bc810c2d27c9f69b79fd2725fa985c896f04c17cef00b54"
    }
  },
  {
    "ts": null,
    "headline": "Arrowhead Says Its Gene Silencer Doubled Zepbound's Weight Loss",
    "summary": "Arrowhead Pharmaceuticals said Tuesday its gene-silencing approach almost doubled the four-month weight-loss with tirzepatide.",
    "url": "https://finnhub.io/api/news?id=5705a49c364387fc6554c785fab084c4ce6466a93f55c2129d6b008796359e2c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767702627,
      "headline": "Arrowhead Says Its Gene Silencer Doubled Zepbound's Weight Loss",
      "id": 138000127,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Arrowhead Pharmaceuticals said Tuesday its gene-silencing approach almost doubled the four-month weight-loss with tirzepatide.",
      "url": "https://finnhub.io/api/news?id=5705a49c364387fc6554c785fab084c4ce6466a93f55c2129d6b008796359e2c"
    }
  },
  {
    "ts": null,
    "headline": "Wall Street Lunch: D-Wave Quantum Shows Industry First On-Chip Cryogenic Control Of Qubits",
    "summary": "D-Wave Quantum (QBTS) says it has successfully completed an industry first: scalable, on-chip cryogenic control of qubits.",
    "url": "https://finnhub.io/api/news?id=c9ae88d53b23cd75921835f8b0c70b42438d472f85979a42f29a676ee189a6f0",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767697100,
      "headline": "Wall Street Lunch: D-Wave Quantum Shows Industry First On-Chip Cryogenic Control Of Qubits",
      "id": 138001014,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2216190568/image_2216190568.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "D-Wave Quantum (QBTS) says it has successfully completed an industry first: scalable, on-chip cryogenic control of qubits.",
      "url": "https://finnhub.io/api/news?id=c9ae88d53b23cd75921835f8b0c70b42438d472f85979a42f29a676ee189a6f0"
    }
  },
  {
    "ts": null,
    "headline": "Big Pharma Has More Going for It Than Obesity Drugs",
    "summary": "Pharmaceutical companies are getting a fresh look for a range of drugs in development, plus a regulatory reprieve.",
    "url": "https://finnhub.io/api/news?id=a61b717e4912048699622837b155b7181980706cef9754ab377060d2b9aba00a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767695400,
      "headline": "Big Pharma Has More Going for It Than Obesity Drugs",
      "id": 137999357,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Pharmaceutical companies are getting a fresh look for a range of drugs in development, plus a regulatory reprieve.",
      "url": "https://finnhub.io/api/news?id=a61b717e4912048699622837b155b7181980706cef9754ab377060d2b9aba00a"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly's Trifecta: Fundamentals, Undervaluation, And Momentum",
    "summary": "Eli Lilly stays a Strong Buy as GLP-1 demand drives revenue/EPS beats, margin gains, and pipeline upside. Click here to read my latest analysis of LLY stock.",
    "url": "https://finnhub.io/api/news?id=82cf911209d0311d4a18d53719a43ecf6ff521f324ce4f4f7ed0eb63f0c65529",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767694555,
      "headline": "Eli Lilly's Trifecta: Fundamentals, Undervaluation, And Momentum",
      "id": 138000822,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/521503168/image_521503168.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Eli Lilly stays a Strong Buy as GLP-1 demand drives revenue/EPS beats, margin gains, and pipeline upside. Click here to read my latest analysis of LLY stock.",
      "url": "https://finnhub.io/api/news?id=82cf911209d0311d4a18d53719a43ecf6ff521f324ce4f4f7ed0eb63f0c65529"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk: Wegovy Pill Is Not A Game Changer",
    "summary": "Novo Nordisk faces GLP-1 headwinds after the FDA-approved Wegovy pill, and LLY gains share, margins erode, and the pipeline is weak. See why NVO stock is a Hold now.",
    "url": "https://finnhub.io/api/news?id=ed9347c7022616b3f53ba7da81433e024670b0910213a9ea223533564994b734",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767693600,
      "headline": "Novo Nordisk: Wegovy Pill Is Not A Game Changer",
      "id": 138000775,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1675157246/image_1675157246.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Novo Nordisk faces GLP-1 headwinds after the FDA-approved Wegovy pill, and LLY gains share, margins erode, and the pipeline is weak. See why NVO stock is a Hold now.",
      "url": "https://finnhub.io/api/news?id=ed9347c7022616b3f53ba7da81433e024670b0910213a9ea223533564994b734"
    }
  },
  {
    "ts": null,
    "headline": "The Zacks Analyst Blog Eli Lilly, Medtronic, Intuitive Surgical, Regeneron Pharmaceuticals and Johnson & Johnson",
    "summary": "Eli Lilly highlights how AI is transforming healthcare, from drug discovery to diagnostics, turning defensive medical stocks into growth plays for 2026.",
    "url": "https://finnhub.io/api/news?id=242975ff118acdfa8cc397816bfab4fe69f8920d13f51886cda1ad7806ae12b1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767692400,
      "headline": "The Zacks Analyst Blog Eli Lilly, Medtronic, Intuitive Surgical, Regeneron Pharmaceuticals and Johnson & Johnson",
      "id": 137999358,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly highlights how AI is transforming healthcare, from drug discovery to diagnostics, turning defensive medical stocks into growth plays for 2026.",
      "url": "https://finnhub.io/api/news?id=242975ff118acdfa8cc397816bfab4fe69f8920d13f51886cda1ad7806ae12b1"
    }
  },
  {
    "ts": null,
    "headline": "Zacks Investment Ideas feature highlights Pagaya, Eli Lilly and Weatherford",
    "summary": "Pagaya, Eli Lilly and Weatherford have been highlighted in this Investment Ideas article.",
    "url": "https://finnhub.io/api/news?id=8d06d3a3eb03703b23fdb81d1c9364db80ba668282b89810bdc0570f1bd0332e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767692040,
      "headline": "Zacks Investment Ideas feature highlights Pagaya, Eli Lilly and Weatherford",
      "id": 137999311,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Pagaya, Eli Lilly and Weatherford have been highlighted in this Investment Ideas article.",
      "url": "https://finnhub.io/api/news?id=8d06d3a3eb03703b23fdb81d1c9364db80ba668282b89810bdc0570f1bd0332e"
    }
  },
  {
    "ts": null,
    "headline": "2 Cash-Producing Stocks to Keep an Eye On and 1 We Ignore",
    "summary": "Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.",
    "url": "https://finnhub.io/api/news?id=107a482d055625d588a6536725fc60fd67300d5fbbaf0dfeea27d618065bda3c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767673986,
      "headline": "2 Cash-Producing Stocks to Keep an Eye On and 1 We Ignore",
      "id": 137999360,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.",
      "url": "https://finnhub.io/api/news?id=107a482d055625d588a6536725fc60fd67300d5fbbaf0dfeea27d618065bda3c"
    }
  }
]